Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423431 · ClinicalTrials.gov registry record
Retrospective Evaluation of a Commercially Available Hydrogel Spacer (BP-009)
A clinical trial, sponsored by BioProtect.
- Completed
- Registry status
- 19
- Enrollment target
NCT05423431: Completed study, sponsored by BioProtect.
NCT05423431 is a clinical trial that has completed, run by BioProtect. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05423431 has completed, sponsored by BioProtect.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
Dosimetry efficacy of the hydrogel spacer.
Primary Outcome
Assessment of rectal radiation exposure as compared between rectal dose volume histograms calculated for pre and post hydrogel injection
Interventions
- OTHER Observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2021-06-30 |
What the finished NCT05423431 record still lists
NCT05423431 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Observation is the first listed.
NCT05423431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05423431 about?
NCT05423431 is a clinical study titled "Retrospective Evaluation of a Commercially Available Hydrogel Spacer (BP-009)". Dosimetry efficacy of the hydrogel spacer.
What is the current status of trial NCT05423431?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2020-11-09. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT05423431?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT05423431?
This trial is sponsored by BioProtect, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI